Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways

Am J Physiol Heart Circ Physiol. 2010 Mar;298(3):H1079-87. doi: 10.1152/ajpheart.00306.2009. Epub 2010 Jan 8.

Abstract

Recent studies have implicated Toll-like receptor 2 (TLR2) and TLR4 signaling in delimiting liver and brain injury following ischemia-reperfusion (I/R). To determine whether TLR2 and TLR4 conferred cytoprotection in the heart, we subjected hearts of wild-type (WT) mice and mice deficient in TLR2 (TLR2D), TLR4 (TLR4D), and TIR domain-containing adapter protein (TIRAP-D) to ischemic preconditioning (IPC). Langendorff-perfused hearts were subjected to 30 min ischemia and 60 min reperfusion with or without IPC. IPC resulted in a significant increase (P < 0.05) in the percent recovery of left ventricular developed pressure (%LVDP) in WT mouse hearts (54.4 +/- 2.7% of baseline), whereas there was no significant increase in %LVDP (P > 0.05) in TIRAP-D mouse hearts (43.8 +/- 1.9%) after I/R injury. IPC also resulted in a significant (P < 0.05) decrease in I/R-induced creatine kinase release and Evans blue dye uptake in WT but not TIRAP-D hearts. Interestingly, IPC resulted in a significant (P < 0.05) increase in %LVDP in TLR4-deficient hearts (52.7 +/- 3%) but not in TLR2D hearts (39.3 +/- 1.5%). Pretreatment with a specific TLR2 ligand (Pam3CSK) protected WT hearts against I/R-induced left ventricular dysfunction. The loss of IPC-induced cardioprotection in TIRAP-D mouse hearts was accompanied by a decreased translocation of protein kinase C-epsilon and decreased phosphorylation of GSK-3beta. Taken together, these data suggest that the cardioprotective effect of IPC is mediated, at least in part, through a TLR2-TIRAP-dependent pathway, suggesting that the modulation of this pathway represents a viable target for reducing I/R injury.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Disease Models, Animal
  • Glycogen Synthase Kinase 3 / metabolism
  • Glycogen Synthase Kinase 3 beta
  • Immunity, Innate / physiology*
  • Ischemic Preconditioning, Myocardial*
  • Lipopeptides / therapeutic use
  • Male
  • Membrane Glycoproteins / deficiency
  • Membrane Glycoproteins / physiology*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Mutant Strains
  • Myocardial Reperfusion Injury / complications
  • Myocardial Reperfusion Injury / physiopathology*
  • Protein Kinase C-epsilon / metabolism
  • Receptors, Interleukin-1 / deficiency
  • Receptors, Interleukin-1 / physiology*
  • Signal Transduction / physiology*
  • Toll-Like Receptor 2 / deficiency
  • Toll-Like Receptor 2 / physiology*
  • Toll-Like Receptor 4 / deficiency
  • Toll-Like Receptor 4 / physiology
  • Ventricular Dysfunction, Left / etiology
  • Ventricular Dysfunction, Left / prevention & control

Substances

  • Lipopeptides
  • Membrane Glycoproteins
  • Pam(3)CSK(4) peptide
  • Receptors, Interleukin-1
  • TIRAP protein, mouse
  • Tlr2 protein, mouse
  • Tlr4 protein, mouse
  • Toll-Like Receptor 2
  • Toll-Like Receptor 4
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, mouse
  • Protein Kinase C-epsilon
  • Glycogen Synthase Kinase 3